Mucous membrane pemphigoid – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:33:20 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Mucous membrane pemphigoid – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Low-Dose Aldesleukin for Patients with Pemphigus, Mucous Membrane Pemphigoid, Polymyositis, Dermatomyositis, and Primary Sclerosing Cholangitis https://clinicaltrials.eu/trial/study-on-low-dose-aldesleukin-for-patients-with-pemphigus-mucous-membrane-pemphigoid-polymyositis-dermatomyositis-and-primary-sclerosing-cholangitis/ Wed, 29 Apr 2026 14:30:30 +0000 https://clinicaltrials.eu/trial/study-on-low-dose-aldesleukin-for-patients-with-pemphigus-mucous-membrane-pemphigoid-polymyositis-dermatomyositis-and-primary-sclerosing-cholangitis/ This clinical trial is focused on studying the safety and effectiveness of a treatment for several chronic inflammatory diseases. The diseases being studied include Mucous Membrane Pemphigoid, Primary Sclerosing Cholangitis, Pemphigus Vulgaris, and Polymyositis/Dermatomyositis. The treatment being tested is a low-dose form of Interleukin-2, also known by its code name IL-2. This medication is administered as a solution for injection or infusion. The study will also use Glucose as part of the trial.

The purpose of this study is to evaluate the safety and the relationship between the body’s immune response and the clinical outcomes when using low-dose IL-2 therapy in patients with these diseases. Participants will receive the treatment over a period of eight weeks. The study is designed to be randomized, meaning participants will be randomly assigned to different groups, and double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or a placebo. This helps ensure the results are unbiased.

Throughout the study, researchers will monitor the participants’ immune responses and any changes in their disease symptoms. The goal is to understand how the treatment affects the immune system and whether it leads to improvements in the conditions being studied. The trial will help determine if low-dose IL-2 therapy is a safe and effective option for managing these chronic inflammatory diseases.

]]> Study on Rituximab and Cyclophosphamide for Patients with Severe Mucous Membrane Pemphigoid https://clinicaltrials.eu/trial/study-on-rituximab-and-cyclophosphamide-for-patients-with-severe-mucous-membrane-pemphigoid/ Wed, 29 Apr 2026 14:23:01 +0000 https://clinicaltrials.eu/trial/study-on-rituximab-and-cyclophosphamide-for-patients-with-severe-mucous-membrane-pemphigoid/ This clinical trial is focused on studying a condition called mucous membrane pemphigoid, which is a severe autoimmune disease that causes blisters and erosions on mucous membranes such as the mouth, eyes, and throat. The study aims to compare the safety and effectiveness of two treatments: rituximab, which is given as an infusion into a vein, and cyclophosphamide, which is taken as an oral tablet. Both treatments are used in combination with another medication called dapsone. The purpose of the study is to determine which treatment is more effective in achieving remission, meaning a reduction or disappearance of disease symptoms, over a period of 12 months.

Participants in the study will be randomly assigned to receive either rituximab or cyclophosphamide, along with dapsone. Some participants may also receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments. The study will last for up to 12 months, during which participants will have regular check-ups to monitor their health and the progress of their condition. The study will assess how well the treatments work in reducing disease activity and improving the quality of life for those with severe mucous membrane pemphigoid.

The trial will also look at the safety of the treatments by monitoring any side effects or adverse events that occur during the study. This includes tracking any serious health issues that may arise and evaluating the overall tolerance of the treatments. Additionally, the study will measure changes in specific antibodies in the blood that are associated with the disease, to better understand how the treatments affect the underlying immune response. The findings from this study could help improve treatment options for people with severe mucous membrane pemphigoid.

]]>